On May 24, 2012 Patrys reported that it has just been granted a U.S. patent for lead product PAT-SM6 (Press release Patrys, MAY 24, 2012, View Source [SID:1234500549]).
The patent granted by the U.S. Patent Office as US 8,124,080 contains claims that cover the PAT-SM6 antibody binding to low-density lipoprotein (LDL) and components of LDL which are believed to be involved in the mode of action for the product. This is the second U.S. patent that has been granted covering the PAT-SM6 product.
Patrys’ patent applications covering PAT-SM6 offer protection through to at least 2024 with the possibility of an extension of term.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!